Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial

American Journal of Kidney Diseases

Volumn 61, Issue 2, 2013, Pages 211-218

  Fernandez Juarez, Gema ^a   Luño, José ^b   Barrio, Vicente ^c   De Vinuesa, Soledad García ^b   Praga, Manuel ^d   Goicoechea, Marian ^b   Cachofeiro, Victoria ^e   Nieto, Javier ^f   Fernández Vega, Francisco ^g   Tato, Ana ^a   Gutierrez, Eduardo ^d  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f Hospital Alarcos   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

ACE inhibitor; angiotensin receptor blocker; dual blockade; renal progression; Type 2 diabetic nephropathy

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALDOSTERONE; C REACTIVE PROTEIN; CREATININE; IRBESARTAN; LISINOPRIL;

AGED; ALBUMIN BLOOD LEVEL; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPAIN;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; LISINOPRIL; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84872322085     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.07.011     Document Type: Article

References (28)

1. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy The Collaborative Study Group N Engl J Med 329 20 1993 1456 1462
2. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 12 2001 851 860
3. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 12 2001 861 869
4. R. Palla, V. Panichi, V. Finato Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function Int J Clin Pharmacol Res 14 1 1994 35 43
5. H. Peters, W.A. Border, N.A. Noble Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade Kidney Int 54 5 1998 1570 1580
6. A.B. Fogo Progression and potential regression of glomerulosclerosis Kidney Int 59 2 2001 804 819
7. G.D. Laverman, R.H. Henning, P.E. de Jong, G. Navis, D. de Zeeuw Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria Am J Kidney Dis 38 6 2001 1381 1384
8. P. Aranda, J. Segura, L.M. Ruilope Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies Am J Kidney Dis 46 6 2005 1074 1079
9. F.F. Hou, D. Xie, X. Zhang Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency J Am Soc Nephrol 18 6 2007 1889 1898
10. K. Rossing, K.J. Schjoedt, B.R. Jensen, F. Boomsma, H.H. Parving Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 3 2005 1190 1198
11. K.F. Hilgers, J.F. Mann ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease J Am Soc Nephrol 13 4 2002 1100 1108
12. Y. Lacourciere, A. Belanger, C. Godin Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy Kidney Int 58 2 2000 762 769
13. A.H. Barnett, S.C. Bain, P. Bouter Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy N Engl J Med 351 19 2004 1952 1961
14. M. Azizi, G. Chatellier, T.T. Guyene, D. Murieta-Geoffroy, J. Ménard Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives Circulation 92 4 1995 825 834
15. G. Fernandez-Juarez, V. Barrio, S.G. de Vinuesa, M. Goicoechea, M. Praga, J. Luño Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials J Am Soc Nephrol 17 12 2006 S250 S254 (suppl 3)
16. M. MacKinnon, S. Shurraw, A. Akbari, G.A. Knoll, J. Jaffey, H.D. Clark Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data Am J Kidney Dis 48 1 2006 8 20
17. R. Kunz, C. Friedrich, M. Wolbers, J.F. Mann Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease Ann Intern Med 148 1 2008 30 48
18. J. Luño, V. Barrio, M.A. Goicoechea Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies Kidney Int Suppl 82 2002 S47 S52
19. J.F. Mann, R.E. Schmieder, M. McQueen Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicentre, randomised, double-blind, controlled trial Lancet 372 9638 2008 547 553
20. S.W. Tobe, C.M. Clase, P. Gao Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies Circulation 123 10 2011 1098 1107
21. ONTARGET Investigators S. Yusuf, K.K. Teo, J. Pogue et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 15 2008 1547 1559
22. Z. Harel, C. Gilbert, R. Wald The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis BMJ 344 2012 e42
23. S. Bangalore, S. Kumar, I. Lobach, F.H. Messerli Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials Circulation 123 24 2011 2799 2810
24. T.H. Jafar, C.H. Schmid, M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease A meta-analysis of patient-level data Ann Intern Med 135 2 2001 73 87
25. M.J. Klag, P.K. Whelton, B.L. Randall Blood pressure and end-stage renal disease in men N Engl J Med 334 1 1996 13 18
26. S. Klahr, A.S. Levey, G.J. Beck The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease Modification of Diet in Renal Disease Study Group N Engl J Med 330 13 1994 877 884
27. M.J. Sarnak, T. Greene, X. Wang The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study Ann Intern Med 142 5 2005 342 351
28. J.T. Wright Jr, G. Bakris, T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 19 2002 2421 2431